<?xml version="1.0" ?>
<akomaNtoso xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">
  <act name="section">
    <meta>
      <identification source="#publicresource">
        <FRBRWork>
          <FRBRthis value="/us-ga/act/ocga/16-13-25"/>
          <FRBRuri value="/us-ga/act/ocga/16-13-25"/>
          <FRBRdate date="2025-12-31" name="enacted"/>
          <FRBRauthor href="#ga-legislature"/>
          <FRBRcountry value="us-ga"/>
        </FRBRWork>
        <FRBRExpression>
          <FRBRthis value="/us-ga/act/ocga/16-13-25/eng"/>
          <FRBRuri value="/us-ga/act/ocga/16-13-25/eng"/>
          <FRBRdate date="2025-12-31" name="publication"/>
          <FRBRauthor href="#publicresource"/>
          <FRBRlanguage language="eng"/>
        </FRBRExpression>
        <FRBRManifestation>
          <FRBRthis value="/us-ga/act/ocga/16-13-25/eng/akn"/>
          <FRBRuri value="/us-ga/act/ocga/16-13-25/eng/akn"/>
          <FRBRdate date="2025-12-31" name="generation"/>
          <FRBRauthor href="#cosilico"/>
        </FRBRManifestation>
      </identification>
      <references source="#cosilico">
        <TLCOrganization eId="ga-legislature" href="/ontology/organization/us-ga/legislature" showAs="Georgia General Assembly"/>
        <TLCOrganization eId="publicresource" href="https://public.resource.org" showAs="Public.Resource.Org"/>
        <TLCOrganization eId="cosilico" href="https://cosilico.ai" showAs="Cosilico"/>
      </references>
    </meta>
    <body>
      <section eId="sec_16_13_25">
        <num>16-13-25</num>
        <content>
          <p>The controlled substances listed in this Code section are included in Schedule I:</p>
          <p>(Code 1933, § 79A-806, enacted by Ga. L. 1974, p. 221, § 1; Ga. L. 1978, p. 1668, § 6; Ga. L. 1979, p. 859, § 5; Ga. L. 1980, p. 1746, § 4; Ga. L. 1981, p. 557, § 3; Ga. L. 1982, p. 2403, §§ 11, 16; Ga. L. 1984, p. 22, § 16; Ga. L. 1984, p. 1019, § 1; Ga. L. 1985, p. 1219, § 2; Ga. L. 1986, p. 1555, § 3; Ga. L. 1987, p. 261, § 1; Ga. L. 1989, p. 233, § 1; Ga. L. 1990, p. 8, § 16; Ga. L. 1990, p. 640, § 1; Ga. L. 1992, p. 1131, § 1; Ga. L. 1994, p. 169, §§ 1-3, 3.1; Ga. L. 1996, p. 356, § 1; Ga. L. 2001, p. 816, § 1; Ga. L. 2002, p. 415, § 16; Ga. L. 2003, p. 349, § 2; Ga. L. 2005, p. 1028, § 1/SB 89; Ga. L. 2006, p. 219, § 14/HB 1054; Ga. L. 2008, p. 169, §§ 1, 2/HB 1090; Ga. L. 2010, p. 338, § 1/HB 1309; Ga. L. 2010, p. 860, § 1/SB 353; Ga. L. 2011, p. 656, §§ 1, 2/SB 93; Ga. L. 2012, p. 40, §§ 2, 3/SB 370; Ga. L. 2013, p. 5, § 1/HB 57; Ga. L. 2013, p. 71, §§ 1, 1.1/HB 302; Ga. L. 2013, p. 141, § 16/HB 79; Ga. L. 2014, p. 217, §§ 1-3/HB 835; Ga. L. 2015, p. 883, §§ 1, 2/HB 211; Ga. L. 2016, p. 798, §§ 2, 3/HB 783; Ga. L. 2017, p. 14, §§ 1-4/HB 231; Ga. L. 2017, p. 417, §§ 7-1, 7-2/SB 104; Ga. L. 2018, p. 314, §§ 1-4/HB 830; Ga. L. 2018, p. 1112, § 16/SB 365; Ga. L. 2019, p. 820, § 1/HB 483; Ga. L. 2019, p. 1030, § 3/HB 213; Ga. L. 2021, p. 184, § 26/SB 195; Ga. L. 2021, p. 386, §§ 1-4/HB 367.)</p>
          <p>The 2016 amendment,
      effective May 3, 2016, rewrote subparagraph (3)(P); added subparagraphs (3)(BBBB) through (3)(DDDD); deleted subparagraph (12)(L.1), which read: "1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);" substituted "Indole carboxamides" for "(1-Pentylindol-3-yl)-(2,2,3,3 tetramethylcyclopropyl) methanone (UR-144)" in subparagraph (12)(M); substituted "Indole carboxylates" for "[1-(5-fluoropentyl)indole-3yl]-(2,2,3,3 tetramethylcyclopropyl) methanone (XLR11)" in subparagraph (12)(N); substituted "Indazole carboxylates" for "[1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]
   -(2,2,3,3 tetramethylcyclopropyl) methanone (A-796,260)" in subparagraph (12)(P); substituted "Indole tetramethylcyclopropanecarbonyls" for "1-pentyl-3-(1-adamantylamido)indole (2NE1)" in subparagraph (12)(S); substituted "Napthoylbenzimidazoles" for "1-(5-fluoropentyl)-N-(tricyclo[3.31.13,7]de
   c-1-yl)-1H-indole-3-carboxamide (STS-135)" in subparagraph (12)(T); substituted "Naphthoylindazoles" for "N-1-naphthalenyl-1-pentyl-1H-indole-3-c arboxamide (NNEI)" in subparagraph (12)(V); deleted subparagraph (12)(W), which read:
   "N-(1-amino-3,3-dimethyl-1-oxo-
   butan-2-yl)-1-pentyl-1H-indole-3-carboxamide (ADBICA);"; deleted subparagraph (12)(X), which read: "(1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl) (naphthalen-1-yl)methanone (AM-2201 benzimidazole analog);"; deleted subparagraph (12)(Y), which read: "Quinolin-8-yl-1-(4-fluorobenzyl)-1H-in=
   --dole-3-carboxylate (FUB-PB-22);"; deleted subparagraph (12)(Z), which read: "Naphthalen-1-yl-1-(4-fluorobenzyl)-1H-indole-3-ca
   rboxylate (FDU-PB-22);"; deleted subparagraph (12)(AA), which read: "Naphthalene-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxyl
   ate (NM2201);"; deleted subparagraph (12)(BB), which read: "(1-(4-fluorobenzyl)-1H-indol-3-yl) (2,2,3,3-tetramethylcyclopropyl)methanone (FUB-144);"; deleted subparagraph (12)(CC), which read: "N-(1-amino-3-methyl-1-oxobutan-2-yl)-
   1-(5-fluoropentyl) 1H-indole-3-carboxamide (5-fluoro-ABICA);"; and deleted subparagraph (12)(DD), which read: "1-naphthalenyl(1-pentyl-1H-indazol-3-yl)-
   methanone (THJ 018)".</p>
          <p>The 2017 amendments.
      The first 2017 amendment, effective April 17, 2017, added subparagraphs (1)(RR) and (1)(SS); in paragraph (3), reserved subparagraphs (3)(CC), (3)(EE), (3)(JJ), (3)(KK), (3)(LL), (3)(MM), (3)(NN), and (3)(RR), which formerly read: "(CC) 3-methylfentanyl</p>
          <p>"(EE) Para-flurofentanyl</p>
          <p>"(JJ) Alpha-Methylthiofentanyl</p>
          <p>"(KK) Acetyl-Alpha-Methylfentanyl</p>
          <p>"(LL) 3-Methylthiofentanyl</p>
          <p>"(MM) Beta-Hydroxyfentanyl</p>
          <p>"(NN) Thiofentanyl</p>
          <p>"(RR) Beta-Hydroxy-3-Methylfentanyl";</p>
          <p>substituted "Fluoromethcathinone" for "4-Fluoromethcathinone" in subparagraph (3)(FFF); added subparagraphs (3)(EEEE) and (3)(FFFF); in paragraph (4), reserved subparagraphs (4)(B) and (4)(C), which formerly read: "(B) N-(1-benzyl-4-piperidyl)-N-phenylpropanamide (benzyl-fentanyl)</p>
          <p>"(C) N-(1-(2-thienyl)methyl-4-pi-
   peridyl)-N-phenylpropanamide
   (thenylfen-
   tanyl)"; substituted "; and" for the period at the end of subparagraph (12)(V); and added paragraphs (13) through (15). The second 2017 amendment, effective May 8, 2017, added identical subparagraphs (1)(RR) and (1)(SS) and identical paragraphs (13) through (15).</p>
          <p>The 2018 amendments.
      The first 2018 amendment, effective May 3, 2018, added paragraph (3)(GGGG); inserted "or alkoxy substitution" in division (12)(L)(ii); substituted the present provisions of division (13)(E)(ii) for the former provisions, which read: "Acetamide group, which itself can be further substituted with a cyclic alkyl group"; and substituted "diphenylethyl" for "diphenylethy" twice in paragraph (15). The second 2018 amendment, effective May 8, 2018, part of an Act to revise, modernize, and correct the Code, revised punctuation in subparagraph (12)(K).</p>
          <p>The 2019 amendments.
      The first 2019 amendment, effective May 7, 2019, added subparagraph (12)(W). The second 2019 amendment, effective May 10, 2019, added ", but not including such substance when found in hemp or hemp products as such terms are defined in Code Section 2-23-3" at the end of subparagraph (3)(P).</p>
          <p>The 2021 amendments.
      The first 2021 amendment, effective July 1, 2021, added the second sentence in subparagraph (3)(P). The second 2021 amendment, effective May 4, 2021, reserved subparagraphs (1)(K) and (1)(V), which formerly read: "Clonitazene" and "Etonitazene", respectively; added subparagraph (1)(TT); added subparagraphs (3)(HHHH) through (3)(JJJJ); substituted "a cyclic or acyclic" for "an acyclic" in division (12)(L)(ii); substituted a semicolon for a period at the end of division (15)(B)(vi); and added paragraph (16).</p>
        </content>
      </section>
    </body>
  </act>
</akomaNtoso>
